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We tested 259 methicillin-resistant Staphylococcus 
aureus isolates and 2 USA300 ATCC type strains for 
susceptibility to bacitracin and neomycin contained in over-
the-counter antibacterial ointments. Resistance to both 
bacitracin and neomycin was found only in USA300. The 
use of over-the counter antimicrobial drugs may select for 
the USA300 clone. 
C
ommunity-acquired methicillin-resistant Staphylo-
coccus aureus (CA-MRSA) is rapidly spreading 
worldwide. MRSA USA300 is a clone of increasing 
public health concern among rapidly disseminating CA-
MRSA strains in the United States (1). MRSA USA300 is 
designated as sequence type (ST) 8 by multilocus sequence 
typing (MLST) and possesses staphylococcal cassette 
chromosome mec (SCCmec) type IVa. Although the rapid 
dissemination of the USA300 clone may occur because of 
a high virulence level that arises from the production of 
Panton-Valentine leukocidin (PVL) or an existing arginine 
catabolic mobile element (ACME) (2), there is no conclusive 
evidence to support this hypothesis (3). Furthermore, the 
hypothesis cannot account for the rapid dissemination 
of MRSA in countries where USA300 clones are not the 
dominant clones (most European countries, South Korea, 
and Japan) (4–6). In most European countries, the dominant 
CA-MRSA clone is the European clone (ST80, SCCmec 
type IV, PVL positive and ACME negative) (1,4). In South 
Korea, only 1 isolate was a USA300 clone among 138 
MRSA isolates collected from patients with bacteremia 
and soft tissue infection (5). In Japan, the MRSA USA300 
clone is rare (6).
In many cases, soft tissue infection acquired in 
communities was treated by using over–the-counter 
(OTC) drugs called triple-antibiotic ointment (TAO), e.g., 
Neosporin (polymyxin B [PL-B] sulfate, 5,000 units/g; 
bacitracin, 400 units/g; and neomycin, 3.5 mg/g) and 
Polysporin triple ointment (PL-B sulfate, 10,000 units/g; 
bacitracin, 500 units/g; and gramicidin 0.25 mg/g). These 
ointments contain antimicrobial drugs at concentrations 
far exceeding their MICs among S. aureus strains (16–32 
μg/mL [equivalent to 124–248 unit/mL] for PL-B, <1–64 
units/mL for bacitracin, and <1–>128 μg/mL for neomycin) 
(7,8). It is hypothesized that CA-MRSA cases in the United 
States were under the selective pressure of TAOs.
In this study, we tested the susceptibilities of MRSA 
isolates, including the USA300 clone, to the antimicrobial 
drugs in TAOs. We also considered the possible role of 
TAOs in spreading the USA300 clone.
The Study
We selected 222 MRSA isolates that were not 
classiﬁ  ed as the New York/Japan (NY/JP) clone on the 
basis of the absence of SCCmec kdpC (9). In addition, 37 
NY/JP clone-like isolates were used. A total of 259 MRSA 
isolates were tested in our study. Of these 259 isolates, 
227 were collected during 2004–2010 at Nagoya Medical 
Center, and 32 isolates were collected in 2006–2009 at 
Kyoto University Hospital, including 9 USA300 outbreak 
isolates (6). Details of isolates used in this study are 
shown in Table 1. ATCC BAA1556 (USA300 FPR3757) 
(American Type Culture Collection, Manassas, VA, USA) 
and ATCC BAA1717 (USA300-HOU-MR TCH1516) 
strains were also used in our study. Susceptibilities to 
bacitracin and neomycin were tested by the Kirby-Bauer 
disk diffusion method (Becton Dickinson, Franklin Lakes, 
NJ, USA). MICs of bacitracin, neomycin, and PL-B for 
USA300 strains were determined by the agar dilution 
method according to the Clinical and Laboratory Standard 
Institute M07-A8 guidelines (10). To observe interaction 
among these 3 antimicrobial drugs, a double-disk synergy 
test was performed with modiﬁ  cation by using ATCC 
BAA1717 (11).
SCCmec were determined according to the method of 
Hisata et al. (12). Isolates possessing both PVL and arcA 
(13) were analyzed by pulsed-ﬁ  eld gel electrophoresis as 
described in our previous study (9). Moreover, USA300 
isolates were genotyped by MLST (www.mlst.net) and 
staphylococcal protein A (spa) typing (www.spaserver.
ridom.de).
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and the arcA gene. Of these 19 isolates, 18 had been 
collected from Kyoto University Hospital and 1 from 
Nagoya Medical Center (Table 2). All 19 PVL- and ACME-
positive isolates were determined to be ST8 by MLST. 
These isolates showed USA300 PFGE patterns identical to 
ATCC BAA1556 and were of SCCmec type IVa. SCCmec 
elements of other isolates were determined as type I (n = 
4), IIa (n = 37), IIb (n = 52), II untypeable (n = 14), IV (n = 
104), and V (n = 9). The SCCmec element of the remaining 
20 isolates could not be identiﬁ  ed.
The 18 USA300 isolates collected from Kyoto 
University Hospital showed the same spa type (t008). 
However, the 1 USA300 isolate collected from Nagoya 
Medical Center was of spa t190.
ATCC BAA1717 and 9 USA300 isolates collected 
during 2007–2009 at Kyoto University Hospital were 
resistant to both bacitracin and neomycin. The USA300 
isolate detected at Nagoya Medical Center in 2004 was 
bacitracin resistant and neomycin susceptible. The other 9 
USA300 isolates and ATCC BAA1556 were susceptible 
to both drugs (Table 2). Highlander et al. (14) found that 
the bacitracin- and aminoglycoside-resistant genes were 
located on pUSA300-HOU-MR, a plasmid typically 
observed in the USA300 strain TCH1516. The resistance 
to bacitracin and neomycin may depend on the presence 
of the plasmid and may be absent in some USA300 clones.
On the other hand, nearly all MRSA isolates that 
were determined to be a type other than USA300 were 
susceptible to bacitracin. One isolate was determined to 
have intermediate resistance to bacitracin. Also, 11 (4.5%) 
of the 240 MRSA isolates not deemed to be USA300 were 
resistant to neomycin, while 132 (55%) demonstrated 
intermediate resistance (Table 2). A study performed in the 
1990s reported that most MRSA strains were susceptible to 
bacitracin, and many were resistant to neomycin (8). Our 
ﬁ  ndings were consistent with the previous study.
MICs of bacitracin, neomycin, and PL-B were 400 
units/mL, 128 μg/mL, and 400 units/mL, respectively, 
among most USA300 isolates with resistance to both 
bacitracin and neomycin (Table 2). The concentrations of 
neomycin and PL-B in the TAOs were ≈10 to 30× higher 
than the MICs of both drugs. In addition, neomycin and 
PL-B were observed to be weakly synergistic (Figure). 
However, Bearden et al. reported that despite containing 
antimicrobial drugs at concentrations far exceeding their 
MICs among MRSA, PL-B and neomycin ointment, 
or PL-B and gramicidin ointment exhibited deﬁ  cient 
bactericidal activity in time-kill assays (15). Bacitracin 
may thus be required for sufﬁ  cient bactericidal activity. 
Acquiring resistance to bacitracin and neomycin may be 
essential for survival under the selective pressure of TAOs. 
If so, bacitracin resistance should be considered a key 
characteristic of the USA300 clone.
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Table 2. Bacitracin and neomycin susceptibility of MRSA USA300 and other MRSA isolates* 
Bacitracin/neomycin
MRSA USA300 (MICs of bacitracin, neomycin, and polymyxin B)†
Other MRSA Kyoto University Hospital Nagoya Medical Center ATCC type strains
R/R 9 (400, 128, 200–400) 0 BAA1717 (400, 128, 400) 0
R/S 0 1 (400, 0.25, 400)  0 
S/R 0 0  11
I/S 0 0  1 
S/I 0 0  132
S/S 9 (6.25–12.5, 0.25, 400) 0 BAA1556 (6.25, 0.25, 400) 96
Total 18 1 2 240
*MRSA, methicillin-resistant Staphylococcus aureus; ATCC, American Type Culture Collection (Manassas, VA, USA); R, resistant; S, susceptible; I, 
intermediate resistance. 
†MICs are expressed as units/mL for bacitracin and polymyxin B and in ȝg/mL for neomycin. 
Table 1. Source of methicillin-resistant Staphylococcus aureus isolates, Japan, 2004–2010 
Source
Outpatients Inpatients
Health care 
workers
No. community-
acquired infections*
No. hospital-acquired 
infections
No. community-acquired 
infections*
No. hospital-acquired 
infections
Skin and soft tissue 23 7 4 23 0
Bloodstream 0 2 1 19 0
Respiratory tract 0 2 1 17 0
Urinary tract 0 2 2 3 0
Ear 8 0 0 1 0
Eye 3 0 0 3 0
Others 1 1 2 3 0
Carriage 14 10 3 29 0
Screening 50 0 2 20 3
Total 99 24 15 118 3
*Community-acquired infections were determined on the basis of patients’ histories according to Centers for Disease Control and Prevention (Atlanta, GA, 
USA) guidelines (www.cdc.gov/mrsa/diagnosis/index.html). Antimicrobial Ointments and MRSA USA300
TAOs containing bacitracin, neomycin, and PL-B 
are widely used in the United States; thus, bacitracin- and 
neomycin-resistant strains may be selected by the selective 
pressure of the TAOs. Although bacitracin and neomycin 
ointments are also available as OTC drugs in Japan, use of 
the ointments is not widespread. As a result, the selective 
pressure that leads to bacitracin and neomycin resistance is 
weak in Japan.
Conclusions
The emergence of MRSA USA300 depends partly on 
the virulence of MRSA USA300, but it may be inﬂ  uenced 
by usage of OTC drugs. In each country, susceptibilities 
of MRSA USA300 to bacitracin and neomycin should 
be thoroughly investigated, and relationships between 
the dissemination of MRSA USA300 and the usage of 
OTC drugs should be clariﬁ  ed. Such an investigation will 
provide valuable information regarding the emergence of 
organisms resistant to OTC topical antibiotics and likely 
a warning against the indiscriminate use of antimicrobial 
drugs. Further studies are required to validate these ﬁ  ndings.
Acknowledgment
We thank Editage for editing this manuscript for language.
This study was supported by grant H21-Shinkou-Ippan-008 
from the Ministry of Health, Labour, and Welfare of Japan. 
Dr Suzuki is a senior researcher at Aichi Prefectural Institute 
of Public Health, Japan. His research interests include the 
molecular epidemiology of Staphylococcus aureus.
References
  1.   David MZ, Daum RS. Community-associated methicillin-resistant 
Staphylococcus aureus: epidemiology and clinical consequences 
of an emerging epidemic. Clin Microbiol Rev. 2010;23:616–87. 
doi:10.1128/CMR.00081-09
  2.   Diep BA, Stone GG, Basuino L, Graber CJ, Miller A, des Etages 
SA, et al. The arginine catabolic mobile element and staphylococcal 
chromosomal cassette mec linkage: convergence of virulence and 
resistance in the USA300 clone of methicillin-resistant Staphylococ-
cus aureus. J Infect Dis. 2008;197:1523–30. doi:10.1086/587907
  3.   Montgomery CP, Boyle Vavra S, Daum RS. The arginine catabolic 
mobile element is not associated with enhanced virulence in experi-
mental invasive disease caused by the community-associated methi-
cillin-resistant Staphylococcus aureus USA300 genetic background. 
Infect Immun. 2009;77:2650–6. doi:10.1128/IAI.00256-09
  4.   Otter JA, French GL. Molecular epidemiology of community-asso-
ciated meticillin-resistant Staphylococcus aureus in Europe. Lancet 
Infect Dis. 2010;10:227–39. doi:10.1016/S1473-3099(10)70053-0
  5.   Park C, Lee DG, Kim SW, Choi SM, Park SH, Chun HS, et al. Pre-
dominance of community-associated methicillin-resistant Staphylo-
coccus aureus strains carrying staphylococcal chromosome cassette 
mec type IVA in South Korea. J Clin Microbiol. 2007;45:4021–6. 
doi:10.1128/JCM.01147-07
  6.   Nagao M, Iinuma Y, Suzuki M, Matsushima A, Takakura S, Ito Y, 
et al. First outbreak of methicillin-resistant Staphylococcus aureus 
USA300 harboring the Panton-Valentine leukocidin genes among 
Japanese healthcare workers and hospitalized patients. Am J Infect 
Control. 2010;38:e37–9. doi:10.1016/j.ajic.2010.04.214
  7.   Duwe AK, Rupar CA, Horsman GB, Vas SI. In vitro cytotoxicity and 
antibiotic activity of polymyxin B nonapeptide. Antimicrob Agents 
Chemother. 1986;30:340–1.
  8.   Maple PA, Hamilton Miller JM, Brumﬁ  tt W. World-wide antibiotic 
resistance in methicillin-resistant Staphylococcus aureus. Lancet. 
1989;1:537–40. doi:10.1016/S0140-6736(89)90076-7
    9.    Suzuki M, Tawada Y, Kato M, Hori H, Mamiya N, Hayashi Y, 
et al. Development of a rapid strain differentiation method for 
methicillin-resistant  Staphylococcus aureus isolated in Japan by 
detecting phage-derived open-reading frames. J Appl Microbiol. 
2006;101:938–47. doi:10.1111/j.1365-2672.2006.02932.x
10.   Clinical and Laboratory Standards Institute. Methods for dilution 
antimicrobial susceptibility test for bacteria that grow aerobically; 
approved standard. 8th ed. CLSI document M07-A8. Wayne (PA): 
The Institute; 2009.
11.   Leclercq R, Bingen E, Su QH, Lambert Zechovski N, Courvalin P, 
Duval J. Effects of combinations of beta-lactams, daptomycin, gen-
tamicin, and glycopeptides against glycopeptide-resistant entero-
cocci. Antimicrob Agents Chemother. 1991;35:92–8.
12.   Hisata K, Kuwahara Arai K, Yamanoto M, Ito T, Nakatomi Y, Cui 
L, et al. Dissemination of methicillin-resistant staphylococci among 
healthy Japanese children. J Clin Microbiol. 2005;43:3364–72. 
doi:10.1128/JCM.43.7.3364-3372.2005
13.   Zhang K, McClure JA, Elsayed S, Louie T, Conly JM. Novel multi-
plex PCR assay for simultaneous identiﬁ  cation of community-asso-
ciated methicillin-resistant Staphylococcus aureus strains USA300 
and USA400 and detection of mecA and Panton-Valentine leukoci-
din genes, with discrimination of Staphylococcus aureus from co-
agulase-negative staphylococci. J Clin Microbiol. 2008;46:1118–22. 
doi:10.1128/JCM.01309-07
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 10, October 2011  1919
Figure. Double-disk synergy test with 3 disks, bacitracin (B10 disk), 
neomycin (N30 disk), or polymyxin B (PL-B, PB300 disk) was 
performed with USA300 strain ATCC BAA1717. Disks were placed 
at 6 mm (A), 9 mm (B), and 11 mm (C) distance from disk centers. 
Neomycin and PL-B were found to be weakly synergistic.14.   Highlander SK, Hulten KG, Qin X, Jiang H, Yerrapragada S, Mason 
EO Jr, et al. Subtle genetic changes enhance virulence of methicil-
lin resistant and sensitive Staphylococcus aureus. BMC Microbiol. 
2007;7:99. doi:10.1186/1471-2180-7-99
15.   Bearden DT, Allen GP, Christensen JM. Comparative in vitro activi-
ties of topical wound care products against community-associated 
methicillin-resistant Staphylococcus aureus. J Antimicrob Chemoth-
er. 2008;62:769–72. doi:10.1093/jac/dkn272
Address for correspondence: Masahiro Suzuki, 7-6 Nagare, Tsuji-machi, 
Kita-ku, Nagoya 462-8576, Japan; email: masahiro_4_suzuki@pref.aichi.
lg.jp
DISPATCHES
1920  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 10, October 2011
Use of trade names is for identiﬁ  cation only and does not 
imply endorsement by the Public Health Service or by the US 
Department of Health and Human Services.